InvestorsObserver gives Kiniksa Pharmaceuticals Ltd (KNSA) an analyst rating of 73, meaning KNSA is ranked higher by analysts than 73% of stocks. The average price target for KNSA is $29.666 and analysts rate the stock as a strong buy.
Why are analyst ratings important?
Analysts know better than anyone the inner workings of the companies they follow, with the exception of the management of the companies. You can tell a lot about a company by studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in any part of the world can disrupt supply chains or disrupt shopping habits. This allows traders to make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all analysts covering a given security, takes the average of these ratings, and then ranks the averages into percentiles. This provides a much better level of granularity than the three levels provided by traditional buy/hold/sell notations.
What’s going on with Kiniksa Pharmaceuticals Ltd shares today?
Kiniksa Pharmaceuticals Ltd (KNSA) stock is trading at $10.08 at 3:29 p.m. on Wednesday, February 23, down -$0.54, or -5.08% from the previous closing price of $10.62. The stock has traded between $10.05 and $10.69 so far today. The volume today is light. So far, 258,755 shares have been traded with an average volume of 352,557 shares. Click here for the full Kiniksa Pharmaceuticals Ltd stock report.
Stay in the know
Subscribe to our daily morning update newsletter and never miss market news, moves and more.